Tenaya Therapeutics to Present Preclinical Data on TN-401 PKP2 Gene Therapy Program at Heart Rhythm 2022
Abstract Detailing TN-401 Results in PKP2 Mouse Model Accepted for Late-Breaker Oral Presentation
TN-401 IND-Enabling Studies Ongoing, On Track to Submit IND in 2023
TN-401 is Tenaya’s gene therapy candidate being developed for the potential treatment of arrhythmogenic right ventricular cardiomyopathy (ARVC) caused by PKP2 gene mutations. Mutations of the PKP2 gene are the leading genetic cause of ARVC and can result in severe disease, including significant arrhythmia and sudden cardiac death in adults and children. These mutations are estimated to affect more than 70,000 patients in the
Details of the presentation are as follows:
Late-Breaking Clinical Trials: Late Breaking Science session
Oral Presentation: Cardiac AAV:PKP2 Gene Therapy Reduces Ventricular Arrhythmias, Reverses Adverse Right Ventricular Remodeling, Improves Heart Function, and Extends Survival in a Pkp2-Deficient Mouse Model of Arrhythmogenic Right Ventricular Cardiomyopathy (Abstract 7263)
Lead author:
To view full event programming, please visit the Heart Rhythm 2022 website.
About
Forward-Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Words such as “will” and “plans,” and similar expressions are intended to identify forward-looking statements. Such forward-looking statements include, among other things, Tenaya’s plans to present preclinical data on TN-401 at Heart Rhythm 2022; Tenaya’s plan to establish a global natural history study of
View source version on businesswire.com: https://www.businesswire.com/news/home/20220428005460/en/
Investors
IR@tenayathera.com
Media
Ten
wendy@tenbridgecommunications.com
Source: